BioPorto Diagnostics A/S

BioPorto Diagnostics Inc. (US)

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem. 

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, clinicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com. 

To learn more about our products and their availability in your country, visit bioporto.com or follow our LinkedIn pages:

Outside the United States: https://www.linkedin.com/company/bioporto-diagnostics-a-s/

Within the US: https://www.linkedin.com/company/bioporto-diagnostics-inc-us/

Social Media Community Guidelines: https://bioporto.com/social-media/

BioPorto A/S

Happy holidays everyone. We look forward to improving kidney care in #2024.
#AKI #PICU #NGAL4kids #KidneyHealthforAll

BioPorto Diagnostics A/S
BioPorto Diagnostics Inc. (US)

HC Andersen Capital hosts CEO Tony Pare with an update for the #investor community, addressing the common questions related to the FDA’s clearance of ProNephro AKI™ (NGAL) – the first biomarker assay for pediatric AKI risk assessment. #FDA #medicaldevices 
 
Watch the presentation at: https://bit.ly/48efBlU
 
Learn more about ProNephro AKI (NGAL) at: https://bit.ly/4aa7fOh

BioPorto is excited to announce that it has received FDA clearance for ProNephro AKI™ (NGAL). This is the first FDA-cleared assay for pediatric AKI risk assessment.
 
“Now, clinicians will have a new and biologically credible AKI test at their disposal,” said BioPorto’s Senior Medical Director Dr. Prasad Devarajan.
 
The road to clearance:
BioPorto’s NGAL test received FDA Breakthrough Device Designation in 2019. In 2020, at the height of COVID, the BioPorto team conducted a reference range study with local events across the USA – thank you to our families, friends, and new believers in saving kidneys. Thanks to 16 US children’s hospitals and their committed staff, the EARNEST cutoff study and GUIDANCE clinical trial with 660 patients enrolled were completed.
 
Extensive studies were run, and many reports were created by BioPorto’s R&D, medical, clinical and regulatory employees (past & present), culminating in a pediatric FDA De Novo submission in November 2022. Additional information was provided to FDA in June 2023 and in September 2023, the regulatory pathway was changed to a 510(k).
 
We recognize and appreciate our investors for their loyalty and financial support throughout the entire journey to FDA clearance.
 
Next step: US commercialization:
 “With the FDA’s 510(k) clearance for ProNephro AKI (NGAL) on the Roche cobas® c 501 analyzer, we are excited to launch BioPorto’s US commercialization efforts,” said Tony Pare, BioPorto’s Chief Executive Officer.

Learn more about ProNephro AKI at https://lnkd.in/e9HrtPZw

Nis Glavind Kruse and Helle Helena Kirkemann remind us that, “Thanksgiving is a universal value we can all embrace.” BioPorto gives thanks to our diverse and talented team, our loyal customers, investors, researchers, and clinicians, and our innovative and impactful NGAL products.

Happy Thanksgiving from the BioPorto team!
BioPorto Diagnostics Inc. (US)
BioPorto Diagnostics A/S


Congratulations to our #CEO Tony Pare on his profile in Insights Care. Tony’s #leadership in bringing #diagnostics to market is valued during this exciting time for the company. #medicaldevices 
https://bit.ly/47EESFC

BioPorto Diagnostics A/S
BioPorto Diagnostics Inc. (US)
 

IPhone / Mobile Compatible

Viewport Meta

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

HSTS

Google Maps

Member Board of Directors

Julie McDonough

Chief Executive Officer

Tony Pare

Director

Kevin Redmond

Director of Product Management and Marketing

Robb Morse

Business Development Manager

Craig Braswell

Dave Ferris

Marketing Manager

Sheila Schwabe

Vice President Global Reporting & Controls

George Rosa

Chief Operating Officer

Jan Andersen

Technical Application Specialist

Janie Hendrix

Michael S. Singer

Ole Larsen

Peter Mørch Eriksen

Judi Smith

Vice President, Clinical/Regulatory

Jennifer Zonderman

VP Global Marketing and US Commercialization

Health Care Public Companies With Less Than $10M in Revenue

Europe Public Companies With Fewer Than 50 Employees

Scandinavia Health Care Companies

European Union (EU) Public Companies

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Their pioneering product portfolio includes assays for underserved disease states, such as NGAL for acute kidney injury. They sell their products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the Nasdaq Copenhagen stock exchange.

Post-IPO Equity - BioPorto Diagnostics

Hellerup

Hovedstaden

Denmark

Europe

BioPorto Diagnostics

Immundiagnostik, Inc. Partners with BioPorto Diagnostics A/S to Expand Renal Research Offering

BioPorto Diagnostics A/S on LinkedIn: #aki #ngal #biomarker #criticalcare #nephrology

First Acute Kidney Injury Diagnostic Test Wins FDA Clearance - Research Horizons

Renal Biomarkers Market is expected to grow at a CAGR of 9.1% during the forecasted period | Evolve Business I

United States

North America

India

Asia

HyTest is a competitor of BioPorto, specializing in in-vitro diagnostics and providing a range of products and services for the pharmaceutical industry.

HyTest

Creative Diagnostics is a Denmark-based company that competes with BioPorto in the development and commercialization of monoclonal antibodies and biomarker assays for the pharmaceutical industry.

Creative Diagnostics

Sekisui is a competitor of BioPorto, providing in-vitro diagnostic products and services for healthcare professionals in clinical and research settings.

Sekisui

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers. The company uses its expertise in antibodies and assay development to create a pipeline of novel products that focus on conditions with significant unmet medical need, particularly in the diagnosis and risk assessment of Acute Kidney Injury (AKI).

BioPorto A/S, an in-vitro diagnostics company, provides biomarker tests and tools, and antibodies for clinicians and researchers in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. The company was incorporated in 1917 and is based in Hellerup, Denmark.

news impact assignment basic	general	Feb 22, 2024 11:48 AM	df6bb92b
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 22, 2024 11:48 AM	948174b8
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	4cd761bd
crunchbase profile	general	Oct 30, 2024 5:24 AM	cc95277f
li profile	general	Feb 22, 2024 11:48 AM	750bf8a2
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	be3ca958
peers	general
news basic	general	Feb 22, 2024 11:48 AM	6412afaf
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:BIOPORTO

BioPorto

Last Close

1.66

22/11 08:00

Market Cap

913.02M

Beta: -

Volume Today

22.79K

Avg: -